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Innate immunity conferred by the type I interferon is
critical for antiviral defense. To date only a limited
number of tripartite motif (TRIM) proteins have
been implicated in modulation of innate immunity
and anti-microbial activity. Here we report the
complementary DNA cloning and systematic analy-
sis of all known 75 human TRIMs. We demonstrate
that roughly half of the 75 TRIM-family members
enhanced the innate immune response and that
they do this at multiple levels in signaling pathways.
Moreover, messenger RNA levels and localization
of most of these TRIMs were found to be altered
during viral infection, suggesting that their regulatory
activities are highly controlled at both pre- and post-
transcriptional levels. Taken together, our data
demonstrate a very considerable dedication of this
large protein family to the positive regulation of the
antiviral response, which supports the notion that
this family of proteins evolved as a component of
innate immunity.
INTRODUCTION
The innate immune system forms the first line of defense against
invading pathogens. Host cells recognize incoming pathogen-
associated molecular patterns (PAMPs) by various pattern-
recognition receptors (PRRs), such as the Toll-like receptors
(TLRs) and the RIG-I-like receptors (RLR) (Yoneyama and Fujita,
2010). Intracellular signaling pathways downstream of the PRRs
eventually mediate the induction of inflammatory cytokines,
chemokines, and type I interferons (IFNs), which are critical for
antimicrobial activity (Takeuchi and Akira, 2010).
Recently, a few members of the tripartite motif (TRIM) family
have been implicated in regulation of these innate immune path-
ways (Akira et al., 2006; McNab et al., 2011). The TRIM protein384 Immunity 38, 384–398, February 21, 2013 ª2013 Elsevier Inc.family counts over 70 distinct members in humans. All TRIM
proteins share an N-terminal tripartite motif that consists of
a combination of a really interesting new gene (RING) domain,
one or two B-boxes, and a coiled coil. Some TRIM-like proteins
lack one or more of these domains, yet share signature domains
in their C-terminal part that are in part shared among members
of 11 distinct structural and functional TRIM groups (Ozato
et al., 2008).
The number of TRIMs has rapidly expanded in vertebrate
evolution (Ozato et al., 2008). The expansion of a large proportion
of the recently evolved TRIMs shows parallels with the expan-
sion of immune receptors in evolution (Rhodes et al., 2005).
We hypothesized that TRIMs may be an integral part of the
mechanisms to control immune responses in humans and that
more TRIMs regulate innate immune responses than the handful
described thus far (Kawai and Akira, 2011). To that end we
systematically analyzed all human TRIM proteins for their regula-
tory roles in efficient initiation and signaling of innate immunity by
overexpression andmessenger RNA (mRNA) targeting. Our data
indicate that nearly half of all 75 distinct TRIM proteins positively
regulate the innate immune system.
RESULTS
TRIM Splice Forms Lack Key Domains
Several TRIM genes are known to encode for protein isoforms
that lack functional domains due to alternative splicing. We first
determined whether this heterogeneity is shared by most
members of the family. Bioinformatics analysis of full-length
TRIM-annotated mRNAs in GenBank using SpliceMiner (Kahn
et al., 2007) was performed. This analysis that identifies the
exon composition of each TRIM sequence—thuswithout predic-
tion from genomic DNA sequences—revealed that almost 90%
of all TRIMs have more than one splice variant (see Table S1
available online). In the case of TRIM proteins that are being
heavily investigated, several of these reported splice variants
have been validated and found to be expressed (Cuchet et al.,
2011; Gack et al., 2008). Moreover, this analysis showed that
52% of the TRIM splice forms lack potential key domains such
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TRIM Proteins Regulate Innate Immunityas RING or SPRY (Figure 1A), domains shown to be critical for
e.g., RIG-I activation by TRIM25 (Gack et al., 2007), suggesting
possible negative regulation of the activity of a given full-length
TRIM protein by its splice forms. As functionally characterized
TRIM proteins have mostly been studied in the context of the
longest isoforms, we cloned an isoform of almost every TRIM
containing all predicted conserved domains. To facilitate their
detection, we included an HA-tag or V5-tag (Supplemental
Information). In a few cases, we were unable to clone the TRIM
isoform with all reported domains. In those few instances, we
cloned a shorter isoform (Supplemental Experimental Proce-
dures). Taken together, these results suggested that various
different isoforms of each TRIM may exist. To allow us to study
the effects of individual TRIMs on innate immune regulation,
single cloned isoforms were exogenously expressed from plas-
mids in subsequent studies.
A Large Proportion of TRIMs Is Turned Over
by the Proteasome
We first validated expression of the TRIM proteins in HEK293T
cells and anticipated molecular weight. Most TRIM proteins
contain a RING domain, which can confer ubiquitin ligase activity
and mark proteins for degradation by the proteasome (Fang
et al., 2003). Therefore, expression of all constructs was tested
both in the presence or absence of the proteasome inhibitor
lactacystin. Immunoblot analysis showed a great variation in
the expression of the individual TRIMs compared to GST
which was used as a control throughout this study (Figure 1B;
Table S1). Moreover, many TRIMs were only detected in the
presence of lactacystin, indicating their constant turnover by
the proteasome.
Six TRIMs (TRIM24, TRIM42, TRIM43, TRIM59, TRIM60, and
TRIM75) were never detectably expressed (Figure 1B; Table
S1). In general, all TRIMs whose expression was detectable by
immunoblot ran in SDS-PAGE at their predicted molecular
weights, except for TRIM19, TRIM47, and TRIM54, which ran
at a slightly higher molecular weight than anticipated. This
may have resulted from posttranslational modifications such
as sumoylation, as has been shown for TRIM19 (Lallemand-
Breitenbach et al., 2001). In contrast, the major product from
the TRIM62 plasmid ran lower than expected, although a specific
less expressed product was detected at the predicted molecular
weight (Figure 1B).
A Screening System to Identify Activators and
Enhancers of Innate Immunity
All TRIM clones were tested for their ability to activate the IFN-b
promoter, a nuclear factor kB (NF-kB) responsive promoter
and the IFN-stimulated gene 54 (ISG54) IFN-stimulated
response element (ISRE) in reporter assays. In order to identify
TRIM proteins that induced the reporters by themselves as
well as TRIMs that could enhance antiviral innate immune
responses, we established a reporter assay with the respec-
tive reporter constructs in the presence of 2 ng of plasmid ex-
pressing the two CARD domains of retinoic acid inducible
gene I (RIG-I), thereby constitutively inducing the reporters
(Yoneyama et al., 1998). The resulting 5–50 fold induction by
RIG-I(2CARD) was roughly 1% of the maximum induction and
created a window for coexpressed TRIM proteins to furtherenhance reporter induction by approximately 50- to 100-fold
(Figure 1C and Figure S1A; Figure 1 demonstrates e.g., a 38-
fold window).
The assay was validated using TRIM21 and TRIM25 which
were previously reported to enhance IFN induction (Gack et al.,
2007; Yang et al., 2009; Yoshimi et al., 2009). We observed
that certain highly expressed proteins such as TRIM21 and
TRIM25 maximally enhanced the promoter construct when
transfecting 50 ng plasmid, whereaswith ten timesmore plasmid
the induction was lost (Figure 1C). Other TRIMs maximally
induced the reporter at 500 ng transfected construct (data not
shown). Taken together, these results demonstrated successful
establishment of a screening assay to identify positive regulators
of the type I IFN system.
A Large Number of TRIMs Enhances Innate Immune
Responses
Using these conditions, all TRIM constructs were separately
screened at 50 ng and 500 ng using the IFN-b, ISRE and
NF-kB promoter reporters. An unprecedented number of TRIMs
activated at least two of the reporters to varying degrees above
the GST and RFP controls (Figure S1B). TRIM19 (PML) and
TRIM33were the onlymembers that consistently downregulated
RIG-I(2CARD)-induced signaling (Figure S1B).
All TRIMs inducing the transcription of a particular reporter
above the average induction in that experiment were classified
as a hit. We empirically determined that using the average induc-
tion within each assay as a cut-off, effectively eliminated false-
positives (both occurring from assay variation and low-level
positive feedback loops). Data from all screens were clustered
into a heat-map based on the subset of promoters they induced
(Figure 1D). Overall, 12 TRIMs (16%of total) induced two ormore
reporters exclusively at 50 ng, whereas 15 TRIMs (20% of total)
induced two or more reporters exclusively at 500 ng (Figure 1E).
Ten TRIMs (13% of total) induced two or more reporters at
both concentrations (Figure 1E). TRIMs from all 11 subgroups
were found tomodulate innate immunity (Figure 1F). Importantly,
TRIM5, TRIM8, TRIM21, TRIM23, TRIM25, and TRIM56 that
were previously reported to positively modulate innate immune
responses (Arimoto et al., 2010; Gack et al., 2007; Pertel et al.,
2011; Toniato et al., 2002; Tsuchida et al., 2010; Yang et al.,
2009; Yoshimi et al., 2009) were identified as hits in the screen
(Figures 1D–1F; Figure S1B), thus validating the experimental
approach.
Most TRIMs Are Innate Immune Enhancers Rather Than
Direct Activators
Because the screen described above was performed in the
presence of limited amounts of the innate immune inducer
RIG-I(2CARD)—and thus would identify TRIMs directly induc-
ing or enhancing RIG-I(2CARD)-mediated innate immune
responses—we next performed experiments to determine the
mechanism by which individual hit-TRIMs induce or modulate
responses and in what part of the induction pathway they
roughly function.
To identify which of the hits would induce IFN signaling without
additional stimulation, we expressed the hit-TRIMs from both the
50 and 500 ng groups in the absence of RIG-I(2CARD) plasmid
and analyzed their ability to induce the ISRE promoter. NoneImmunity 38, 384–398, February 21, 2013 ª2013 Elsevier Inc. 385
Figure 1. An Unprecedented Number of TRIMs Enhances Innate Immune Responses; See Also Figure S1 and Table S1
(A) All known TRIM splice variant sequences were mapped using SpliceMiner and the number of distinct proteins they encode determined. These data were used
to determine which of previously identified conserved domains they harbor by NCBI CCD.
(legend continued on next page)
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additional stimulus at 50 ng plasmid (Figure 2A). However,
TRIM9—and to a lesser extent TRIM5, TRIM50, TRIM66, and
TRIM67—induced the ISRE promoter in the absence of a priming
stimulus at 500 ng (Figure 2B). Taken together, these data
suggest that most of the TRIM proteins enhance innate immune
signaling, rather than confer direct activation. In contrast, TRIM5,
TRIM9, TRIM50, TRIM66, and TRIM67 may directly facilitate
innate immune activation.
Next, we set out to identify at which point in the IFN-b induction
pathway individual TRIMs function as enhancers. To this end, we
transfected hit-TRIM plasmids in the presence of limiting
amounts of the established signaling molecules TBK1, IKKε,
and IRF3, which function sequentially downstream of RIG-I in
the IFN-b induction pathway (Figure 2C).
In pilot experiments we determined that only under the
conditions where we transfected 500 ng of TRIM plasmid, the
experimental window (50- to 150-fold enhancement by TRIMs;
Figure S1B and data not shown) allowed for significant and
consistent pathway mapping using this method. Hence, 19
TRIMs identified to enhance limited RIG-I(2CARD) stimulation
at 500 ng were investigated for their enhancing effects on the
further ‘‘downstream’’ signaling molecules TBK1, IKKε, and
IRF3. Indeed, although 19 TRIMs were shown to enhance
RIG-I-mediated signaling under these conditions (Figure 1D),
only 11 and 10 TRIMs enhanced TBK1- and IKKε-mediated
IFN promoter induction above average, respectively (Figures
2D and 2E). This number further decreased to only six TRIMs,
when stimulated with the further downstream signaling molecule
IRF3 (Figure 2F).
The more limited experimental window using only 50 ng of
TRIM plasmid prevented us to perform these analyses in the
presence of TBK1 or IKKε. However, in the presence of IRF3,
the experimental window was sufficient to identify TRIMs that
enhanced IFN induction at 50 ng. Similar to the 500 ng condi-
tions, only seven out of 19 tested TRIMs were still able to
enhance the signal at this degree of induction (Figure 2G).
Together, these data show that the number of TRIMs that can
enhance inducers, declines the further ‘‘down’’ these stimuli
are in the IFN pathway (Figure 2H). This suggests that individual
TRIMs act at various different levels along the IFN-b induction
route.
To explore where individual TRIMs function, these data were
combined in a heatmap (Figure 2I). The last stimulus in the
pathway at which each individual TRIM still enhances provides
an indication of the point at which each TRIM exerts its function.
We thus predict that eight of the tested TRIMs function between
RIG-I and TBK1-IKKε (Figure 2I; T3, T13, T23, T24, T37, T38, T45,(B) HEK293T cells were transfected with plasmids encoding individual TRIM prote
expression of tagged TRIM proteins was analyzed by immunoblot.
(C) TRIM21 and TRIM25 were expressed for 50 ng or 500 ng plasmid by transfecti
active RIG-I(2CARD) plasmid and assayed for their ability to further enhance the
(D) All TRIM proteins were analyzed for their ability to further enhance IFNb, NF
RIG-I(2CARD). TRIMs enhancing reporter activity above average were marked
promoters in the presence of either 50 ng or 500 ng TRIM plasmid.
(E) Overlap and separation of TRIMs enhancing innate immunity in reporter assa
(F) Distribution of screen hits among the TRIM subgroups as defined by Ozato et
RBCC (RING, B-box, coiled-coil) domains are shown as unclassified. TRIMs th
C-terminal domains are as follows: ARF, ADP ribosylation factor-like; BR, bromoT55), four TRIMs between TBK1-IKKε and IRF3 (T36, T42, T60,
T61) and two TRIMs at the point of IRF3 or downstream of it
(T1, T49). Furthermore, five TRIMs (T5, T9, T50, T66, T67) may
work as direct inducers, of which we could not determine the
rough point of action in the induction pathway using this assay.
Unexpected ‘‘gaps’’ found in the pathway mapping for TRIM5
and TRIM50 (Figure 2I), we attribute to technical assay variations
and the cut-off for scoring positives, which are often found to
a limited extent in medium-throughput systems such as these.
Overall, these results demonstrate that individual TRIMs func-
tion at different stages of the IFN-b induction pathway. More-
over, the ability of TRIMs to enhance the activation of these
signaling pathways seems stimulus-specific. This strongly
argues that the identified TRIMs in the initial screen with RIG-I
as a stimulus are not mere artifacts.
TRIM-Enhanced Innate Immune Signaling Confers
Antiviral Cytokine Production
The experiments described above were performed using
reporter systems. Next, we set out to validate that a selected
number of the ‘‘hit’’ TRIMs could also enhance antiviral cytokine
production to protect against virus challenge and determine
dependence on RING-mediated E3 ligase activity.
As with the reporter assays, first the amount of RIG-I(2CARD)
plasmid that would minimally induce antiviral cytokine produc-
tion was determined. HEK293T cells were transfected with
increasing amounts of RIG-I(2CARD) plasmid (Figure 3B) and
after 24, 36, and 48 hr, supernatants were transferred to Vero
cells (Figure 3A). These cells can respond to IFN and confer an
antiviral state, yet cannot produce type I IFN themselves. Hence,
any antiviral effect observed in these cells must have originated
from the cytokines in the provided supernatants.
Fifty ng of RIG-I(2CARD) plasmid and higher induced a
maximum measurable amount of cytokines conferring antiviral
effect in a VSV-GFP infection challenge (Figure 3B, left panel).
The amount of antiviral cytokines was reduced in a dose-depen-
dent manner downward until approximately 2 ng of 2CARD
plasmid. The conferred antiviral activity corresponded with
roughly 10–500 IU of IFN in this range (Figure 3B, right panel).
Because 2 ng of 2CARD was just rate-limiting, this amount
was used in the subsequent assay.
As expected, antiviral cytokine production was similar upon
expression of an irrelevant control protein (GST) or empty vector
in the presence of the titrated limited amount of 2 ng RIG-
I(2CARD) plasmid (Figure 3C, red bars) and in its absence
(orange bars). However, coexpression of 50 ng or 150 ng wild-
type TRIM1, TRIM8, TRIM13, TRIM25, TRIM32, or TRIM38
plasmid enhanced the production of antiviral cytokines andins. At 48 hr, p.t. cells were treated with DMSO or lactacystin and subsequently
on in HEK293T cells in the presence of the limiting amount of 2 ng constitutively
IFN-b promoter. Data are represented as mean of triplicates ± SD.
-kB, or ISRE promoter activation by a limiting amount of constitutively active
as hits and plotted in a heatmap combining the results of all three different
ys at 50 ng and 500 ng plasmid.
al. (Ozato et al., 2008). TRIMs which lack at least one domain in the N-terminal
at activate at least one promoter above average are shown in green. TRIM
domain; COS, C-terminal subgroup.
Immunity 38, 384–398, February 21, 2013 ª2013 Elsevier Inc. 387
Figure 2. Most TRIMs Are Innate Immune Enhancers and Act at Different Levels of Innate Immune Signaling; See Also Figure S2
HEK293T cells were transfected with (A) 50 ng or (B) 500 ng TRIM expression plasmid in the absence of additional stimulus and analyzed for ISRE reporter
induction.
(legend continued on next page)
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TRIM Proteins Regulate Innate Immunityreduced VSV-GFP replication to almost undetectable levels (Fig-
ure 3C, bright green bars and adjacent light gray bars). The de-
picted decrease from400% to100% relative GFP represents
near-complete viral inhibition. In contrast, the same TRIMs with
a single cysteine-to-alanine mutation in their RING domains de-
stroying the zinc-finger, were unable to enhance cytokine
production and confer antiviral activity (Figure 3C, light green
and dark gray bars), despite comparable protein expression
levels as their wild-type counterparts (data not shown).
These data suggest that these TRIMs enhance antiviral cyto-
kine production by means of E3 ligase-dependent (and hence
ubiquitin-like molecule-dependent) mechanisms. Moreover,
they confirm and extend the results from the reporter assays
by showing that TRIMs can indeed enhance the production of
biologically functional, antiviral cytokines.
TRIM Proteins Are Regulated at the Transcriptional and
Posttranscriptional Level
Isoform and cell-type specific expression of individual TRIMs
suggested that they may be complexly regulated at both the
transcriptional and posttranscriptional level. In order to address
the complexity of TRIM regulation, we selected 22 members for
further evaluation (Figure S2).
First we identified TRIMs that may require relocalization during
infection for their regulation of innate immunity. The selected
proteins were expressed in HeLa cells and the majority localized
as speckles, microtubule-like fibers or dispersed in the cyto-
plasm (Figure 4A; Figures S3 and S4). A minor fraction of some
TRIMs was detected in the nucleus of mock-infected cells (Fig-
ure 4A; Figures S3 and S4). Upon infection with SeV, seven of
the tested TRIMs relocalized compared to mock-infected cells
(Figure 4A; Figures S3 and S4) as did the positive control IRF-3
(Figure S4).
Overall, the redistribution patterns grouped in five TRIM local-
ization clusters (Figure 4A). Most of the tested TRIMs localized in
the cytoplasm and did not relocalize during infection (Figure 4A,
cluster A). However, the ‘‘strong hits’’ TRIM13 and TRIM61 relo-
calized from the cytoplasm to the nucleus (cluster B), TRIM21
and TRIM50 changed from cytoplasmic dots to a dispersed
cytoplasmic localization (cluster C), and the partially nuclear
TRIM58 relocalized almost exclusively to the cytoplasm (cluster
D). Finally, TRIM9 and TRIM36, which have previously been
described to associate with microtubules through their COS-
domain (Short and Cox, 2006), relocalized from microtubule-
like filaments to a dispersed cytoplasmic distribution (Figure 4A,
cluster E). Taken together, these results show that several of
the potent innate immune stimulators found in the reporter
assays (Figure 1D) relocalize during infection. Future studies
will need to investigate whether relocalization is a cause or
effect of innate immune activation. However, it is tempting to
speculate that the localization of some TRIMs is required for their
regulatory roles.(C) Key regulatory molecules in type I IFN induction used for subsequent assays
cells were transfected with individual TRIMs and limiting amounts of (D) TBK1, (E
IFN-b reporter induction relative to GST controls ± SD.
(H) The percentage of TRIMs enhancing a particular stimulus were plotted relativ
presence of RIG-I(2CARD).
(I) Heatmap summary of pathway mapping; TRIMs enhancing particular stimuli aSubsequently, we analyzed the regulation of the selected
TRIMs at their mRNA level during infection. Two well-character-
ized cell lines of different origin were infected with SeV to
determine whether the selected TRIM proteins are differentially
regulated during infection and if differences between cell types
exist. Mock- and SeV-infected A549 (lung origin) and THP-1
(monocyte origin) cells were subjected to TRIM-specific real-
time RT-PCR during a time course. Detection of IFN-b, ISG15,
and ISG54 mRNA confirmed productive infection (Figure S5A).
IFN-stimulated gene (ISG) expression was already measurable
at 3 hr p.i. in all cell types. IFN is not an ISG and hence was
not stimulated during IFN treatment in any of the cell types, vali-
dating the specificity of the different treatments (Figure S5A).
Most of the detectable TRIMs were differentially expressed at
3 hr after IFN treatment or infection (Figure 4B; Figure S5B) and
clustered in five different main clusters of regulation (Figure 4B).
In A549 and THP-1 cells, the mRNA of TRIM13, TRIM32, and
TRIM36 remained unchanged at all times, whereas TRIM5,
TRIM21, and TRIM25 were upregulated as previously reported
(Carthagena et al., 2009; Rajsbaum et al., 2008). TRIM1 and
TRIM9 mRNA was only upregulated at 3 hr p.t. in A549 cells,
but not in THP-1 s (Figure 4B; Figure S5B). The remaining TRIMs
were upregulated early during treatment in A549s, yet downre-
gulated in THP-1 cells.
Overall, these kinetics demonstrate that although several
TRIMs are regulated comparably in different cell types, most of
them differ in their regulation during infection. The difference in
mRNA expression of specific TRIMs during infection between
A549 and THP-1 cells suggests that the regulatory roles of
some TRIMs may differ between epithelial and myeloid cells.
Attenuated TRIM Expression in Kidney and Lung Cell
Lines Decreases IFN Induction
Next, to demonstrate that the TRIM proteins identified by the
reporter assays are significant enhancers of the IFNsystem,poly-
clonal cell lines stably expressing small hairpin RNAs (shRNAs)
targeting individual TRIMs were made for TRIMs that were
detectable by real-time RT-PCR (Figures S2 and S5). Stable
attenuation of gene expression provides the advantage that
evenmoderate attenuation can considerably lower target protein
levels. Pilot experiments confirmed only specific attenuation of
each targeted TRIM mRNA while not considerably changing the
mRNA expression of the other TRIMs tested (data not shown).
To ensure challenging with a limited amount of stimulus, which
would allow detecting a phenotype, we titrated the amount of
SeV used as an inducer to result in 10- to 50-fold induction of
IFN-b and ISG54 mRNA over mock-infected samples at 4 hr
p.i. (data not shown). To test whether the IFN response was
diminished in cells knocked down for individual TRIMs, all gener-
ated cell lines were mock or SeV infected and analyzed by real-
time RT-PCR for their ability to upregulate IFN-b and ISG54
mRNA (Figure 5A).. To elucidate the level at which individual TRIMs act as enhancers, HEK293T
) IKKε, and (F and G) constitutively active IRF-3. Data are represented as mean
e to the total number identified as positive hits at 500 ng TRIM plasmid in the
bove average are marked in red.
Immunity 38, 384–398, February 21, 2013 ª2013 Elsevier Inc. 389
Figure 3. TRIM Proteins Enhance the Production of Antiviral Cytokines in a RING-Domain-Dependent Manner
(A) Schematic overview of assay.
(B) HEK293T cells were transfected with increasing amounts of RIG-I(2CARD). Supernatants were harvested at 24, 36, and 48 hr p.t., which were used to incubate
Vero cells for 24 hr. As a reference universal IFN dilutions were used (right panel). These Vero cells were infected with VSV-GFP (4 PFU/cell) for 7 hr and their GFP
expression determined using a plate reader.
(C) HEK293T cells were transfected with a limiting amount of RIG-I(2CARD) plasmid (2 ng) and cotransfected with 50 or 150 ng of wild-type or RING point mutant
TRIM plasmid. At 32 hr, p.t. supernatants were transferred to Vero cells for 24 hr, followed by VSV-GFP infection for 7 hr. GFP expression was determined using
a plate reader. Data are represented as mean relative to the background in mock-infected cells ± SD.
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Figure 4. TRIMs Are Complexly Regulated at Both the Transcriptional and Posttranscriptional Level; See Also Figures S3–S5
(A) HeLa cells were transfected with tagged TRIM expression plasmids and incubated for 32 hr. Subsequently, cells were infected with SeV for 8 hr. After fixing,
cells were stained using HA and V5 antibodies recognizing the tagged TRIM proteins. The resulting localization data were organized in five distinct clusters by
similar localization and relocalization patterns. The depicted immunofluorescence figures are representative samples for localization patterns in each distinct
cluster.
(B) Lung-derived A549 and monocyte-derived THP-1 cells were treated with 1,000 IU/mL universal IFN-b or infected with SeV. At 3, 6, and 9 hr p.t. RNA was
isolated and analyzed by real-time RT-PCR for TRIM mRNA expression. The depicted expression figures were drawn by hand to summarize TRIM mRNA
expression patterns in each distinct cluster depicted in Figure S5. TRIM expression regulation was in almost all instances similar upon IFN-b treatment and SeV
infection, and thus represented as single lines.
Immunity
TRIM Proteins Regulate Innate ImmunityIn cells expressing a scrambled shRNA, SeV infection stimu-
lated IFN-b and ISG54 mRNA by 20- to 30-fold (Figure 5B). Vari-
ation among different TRIMs in their mRNA targeting efficiency
ranged from 40% to 90% (Figure 5C). Under those conditions,
IFN-b and ISG54 mRNA induction was reduced by more than
50% in TRIM9 and TRIM13 attenuated cells (Figure 5D). Notably,
those TRIMs were among the strongest inducers in the reporter
assays (Figure 1D).
Also TRIM36-38, TRIM58, and TRIM66 reduced IFN-b and
ISG54 mRNA induction by 20%–50% (Figure 5D). Moreover,
attenuation of TRIM21 and TRIM25 expression, both previ-
ously shown to be required for efficient IFN induction, dimin-
ished IFN-b and ISG54 induction by 40% and 30%, respec-
tively. mRNA targeting of TRIM1, TRIM5, and TRIM32 did not
reduce IFN-b induction despite efficient mRNA depletion of
all three of these TRIMs (Figures 5C and 5D). A549 cells stably
expressing the same shRNAs were similarly attenuated in
expression of ISGs, with the exception of TRIM36, which
was knocked down, yet did not attenuate ISG induction
(data not shown).
Overall, these results demonstrate that individual mRNA tar-
geting of eight out of 11 selected TRIMs reduced IFN-b and
ISG54 mRNA induction during SeV infection. This corroborates
the initial results from the reporter assays and strongly supportsregulatory roles in antiviral innate immune responses for many
TRIM proteins.
Attenuated TRIM Expression in Primary MDDCs
Reduces LPS-Mediated Cytokine Expression
To ensure that these TRIMs indeed have a biological function in
relevant primary innate immune cells, the same shRNA-express-
ing lentiviruses were used to transduce primary human mono-
cytes from four independent donors. These cells were subse-
quently differentiated into monocyte-derived dendritic cells
(MDDCs) and challenged with LPS. Because TLR and RIG-I
pathways converge downstream and share several key regula-
tors, we expected that LPS stimulation would also be regulated
by several of the TRIMs identified in our study as positive regu-
lators of RIG-I mediated innate immunity.
As in the previous experiments using cell lines, the amount of
LPS and time of stimulation were carefully titrated to result in
a limited IFN-b, TNF-a, IL-6, and IL-8 induction, potentially
increasing the window to observe phenotypes. As a conse-
quence of choosing the optimal time point for analyzing IFN-
b and other ‘‘immediate early’’ cytokines (2 hr p.t.), no ISGs
were induced yet at the time of analysis (data not shown).
IFN-b mRNA expression was induced 20- to 200-fold by LPS
compared to mock-treated samples (Figure 6A). Other cytokinesImmunity 38, 384–398, February 21, 2013 ª2013 Elsevier Inc. 391
Figure 5. Stable mRNA Targeting of Endog-
enous TRIMs Decreases IFN-b and ISG54
Upregulation during SeV infection
(A) Schematic overview of assay. HEK293T cells
were transduced with lentiviruses expressing
shRNAs targeting individual TRIMs. After puro-
mycin selection, transduced polyclonal cells were
infected with SeV and analyzed in triplicate by
specific real-time RT-PCR for (B) IFN and ISG54
induction in cells expressing a scrambled shRNA,
(C) specific TRIM expression in all mRNA targeted
cell pools and (D) IFN-b and ISG54 stimulation by
SeV in TRIM mRNA targeted cells. Data are rep-
resented as mean ± SD.
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induction by LPS was similar in transduced and nontransduced
cells, indicating that the transduction procedure per se had no
significant effect on the cells (data not shown). As expected
from human samples—especially analyzing such a substantial
number of conditions and cytokines—some interdonor variation
was observed, both at the amount of cytokine induction by LPS,
as well as in the effect of individual TRIMmRNA targeting on this
induction (Figure 6A).
Despite these interdonor variations, decreased expression of
TRIM8 and TRIM32 consistently reduced IFN-b induction by at
least 10% in all four donors. mRNA targeting of TRIM1 and
TRIM36 also attenuated IFN-b expression in most of the donors.
With a few exceptions, TRIM mRNA targeting in the lower IFN
inducing donors consistently and most-potently attenuated
IFN and ISG induction. Interestingly, both TRIM1 and TRIM32
did not attenuate IFN-b expression in SeV-challenged cell lines
(Figure 5D), yet attenuated induction in LPS-stimulated MDDCs
(Figure 6A), suggesting that cell type- and/or stimulation-
specific differences exist. Both TRIM13 and TRIM25 mRNA
targeting only attenuated IFN-b expression in two of the four
donors. However, for both of these TRIMs one of the nonattenu-
ated donors lacked significant TRIM mRNA targeting (TRIM13,
donor 3; TRIM25, donor 2), which could explain the lack of
phenotype in those particular donors. As observed before in
the cell lines (Figures 5C and 5D), TRIM5 shRNA expression
reduced TRIM5 mRNA expression in all donors, yet did not
reduce IFN-b mRNA expression (Figure 6A). Finally, TRIM38
mRNA targeting in LPS-stimulated MDDCs consistently
increased IFN-b expression in all four donors, which is an oppo-392 Immunity 38, 384–398, February 21, 2013 ª2013 Elsevier Inc.site phenotype compared to SeV-stimu-
lation in the cell lines (Figure 5D).
Together, these data suggest that
TRIM1, 8, 13, 25, 32, and 36 are
enhancers of the IFN-b induction pathway
in MDDCs. The phenotypic differences
between TRIM1 and TRIM32 mRNA
targeting in LPS-stimulated MDDCs and
SeV-stimulated cell lines underscores
that some TRIMs may play only a signifi-
cant role in some cell types or in certain
induction pathways of the type I IFN
response. In support of this notion,
TRIM38 mRNA targeting even yieldeda completely opposite phenotype during the two different
stimulations.
In the same samples, the effect of TRIM mRNA targeting on
expression of TNFa, IL-6, and IL-8 was measured. All three
cytokines were induced in all donors, yet were differentially
attenuated depending on the TRIM that was knocked down
(Figure S6). To allow analysis of the cytokine profiles upon
different TRIM mRNA targeting conditions, we plotted the
attenuation of all four measured cytokines among different
donors in a heat map (Figure 6b). The predominant effect of
mRNA targeting of a particular TRIM on a particular cytokine
was plotted as red-orange (indicating downregulation of the
cytokine response and thus mRNA targeting of an enhancer) or
green (to represent increased cytokine expression, indicating
attenuation of a repressor).
As described above, TRIM5 and TRIM38 mRNA targeting
overall increased, rather than attenuated, expression of all
cytokines. Although this phenotype was similar to TRIM5
mRNA targeting in cell lines (Figure 5C), TRIM38 attenuation re-
sulted in the complete opposite upon LPS stimulation. To test
whether the inverted phenotype upon TRIM38 mRNA targeting
resulted from different cell types or different stimuli, we also in-
fected MDDCs (expressing either aTRIM5 or aTRIM38 shRNAs)
from donors 3 and 4 with SeV and analyzed their cytokine
profiles by RT-qPCR.
Levels of the RIG-I-inducing SeV defective-interfering (DI)
RNA (Baum et al., 2010) were not different between samples
(data not shown). In addition, IFN-b mRNA levels had already
reached maximum induction at the time of analysis and hence
did not show any significant differences upon TRIM mRNA
Figure 6. mRNA Targeting of Endogenous TRIMs in MDDCs Attenuates Cytokine Expression upon LPS Stimulation; See Also Figure S6
MDDCs transduced with lentiviruses expressing TRIM-specific shRNAs were stimulated with LPS. Each condition was repeated in four different donors, with 2–4
wells per condition per donor.
(A) At 2 hr p.t., cells were harvested and their IFN-b mRNA levels determined by RT-qPCR and plotted as fold induction over mock-induced samples.
(B) Similarly, TNF-a, IL-6, and IL-8 mRNA levels were determined and plotted as a heatmap representing the fraction of donors in which expression of a particular
cytokine was >10% affected compared to the scrambled shRNA control. Red-orange colors show 50% ormore of the donors exhibited consistent attenuation of
the cytokine response upon TRIM mRNA targeting without an equal number of donors with the opposite phenotype. Green colors show 50% or more of the
donors consistently upregulated cytokine responses during TRIM mRNA targeting without an equal number of donors with the opposite phenotype.
(C) MDDCs from donors 3 and 4 expressing TRIM5 or TRIM38 specific shRNAs, were infected with SeV. At 4 hr p.i., their cytokine mRNA levels were
determined by RT-qPCR and plotted as fold induction over mock-induced samples. Numbers in parentheses indicate TRIM mRNA targeting levels (higher
numbers represent better mRNA targeting); n.d. indicates that mRNA targeting could not be reliably measured resulting from low TRIM mRNA levels. Data are
represented as mean ± SD.
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Figure 7. TRIM Proteins Differentially Regulate Various Innate Signaling Pathways; See Also Figure S7 and Table S2
THP1 monocyte-like cells were transduced with lentiviruses expressing a scrambled control shRNA or two individual, different shRNAs targeting the
indicated TRIMs.
(legend continued on next page)
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TRIM Proteins Regulate Innate Immunitytargeting (data not shown). However, TNF-a, ISG15, and ISG54
had not reached maximum induction yet and were analyzed for
attenuation upon TRIM mRNA targeting. As before, TRIM5
mRNA targeting did not attenuate cytokine expression or
expression of ISGs (Figure 6C), whereas TRIM38—in contrast
to LPS stimulation—now attenuated expression of TNF-a and
the two ISGs tested in both donors (Figure 6C). IL-6 and
IL-8 were not consistently changed in both donors (data not
shown).
Taken together, these results show that the majority of the
tested TRIMs are positive regulators of cytokine expression
and this effect may be cell-type specific. However, the opposite
phenotypes observed for TRIM38 mRNA targeting show that the
effect of some TRIMs is induction pathway specific.
TRIM Proteins Regulate Innate Immune Signaling
Originating from Different PRRs
The results of the pathwaymapping by exogenous TRIM expres-
sion (Figure 2) indicated that TRIM proteins act at different levels
of the IFN induction cascade. We set out to complement these
results by mapping the effects of TRIM mRNA targeting on cyto-
kine expression in the context of biologically relevant and more
complex stimuli.
To this end, monocyte-like cells (THP-1) were transduced with
two distinct, individual shRNAs targeting six individual TRIMs
(Figure S7A). Significant TRIM mRNA targeting was confirmed
by specific RT-qPCR (Figure 7A). These cells were subsequently
stimulated with four different stimuli mediating cytokine expres-
sion via distinct receptors and signaling pathways: SeV (through
RIG-I and MAVS), zymosan (through TLR2 and MyD88), poly I:C
(through TLR3 and TRIF), and LPS (through TLR4, TRIF, and
MyD88). This experimental setup allowed (1) confirming attenu-
ation of cytokine expression by TRIMmRNA targeting in an addi-
tional cell type, (2) ruling out shRNA off-target effects by using
multiple distinct shRNA sequences, and (3) mapping in which
innate immune signaling pathways individual TRIM proteins
exert their activity.
SeV infection induced IFN-b mRNA at 3 hr p.i. approximately
by 1,000-fold compared to mock-infected cells (Figure 7B),
which increased further up to 10,000-fold by 6 hr p.i. (data not
shown). This induction was paralleled by both ISG54 and IL6
mRNA, albeit to a lesser absolute extent. In contrast, viral RNA
replication was already maximal at 3 hr p.i. At this time point,
mRNA targeting of the six tested TRIMs (T1, T8, T13, T25, T32,
T38) attenuated IFN-b and ISG54 expression for all shRNAs
tested by 2- to 8-fold compared to the scrambled shRNA
control (Figure 7C: black and gray bars). This reduction did not
result from reduced SeV replication, because SeV RNA levels
were similar or even higher than in the scrambled control (Fig-
ure 7C, orange bars).(A) After puromycin selection, mRNA targeting of individual TRIMs was confirme
stimulated with (B and C) SeV (3 hr; RIG-I-MAVS axis), or (D and E) LPS (3 hr; TLR
ISG54, and IL6 mRNA induction determined by RT-qPCR. Data are represented
(F) Heatmap summary of results from cytokine induction in mRNA targeted cells
withR35% attenuation in cytokine induction are marked in red, or inversely mar
(G) Vero cells were incubated for 24 hr with supernatants from THP1mRNA target
infected for 7 hr with VSV-GFP (4 PFU/cell). Data are represented as mean ± SD
(H) Model-overview of predicted levels of action of the tested subset of TRIMs.In contrast to IFN-b and ISG54, TRIMmRNA targeting resulted
in elevated proinflammatory IL6 expression (Figure 7C, green
bars). Thus, TRIM mRNA targeting with different shRNA
sequences attenuated IFN-b and ISG54 expression in THP1
cells, confirming our findings in HEK293T and MDDCs (Figures
5 and 6) that the tested TRIMs act as positive regulators in the
RIG-I-mediated IFN induction pathway.
Subsequently, cells were stimulated in similar experiments
with zymosan (TLR2; Figures S7B and S7C), poly I:C (TLR3,
Figures S7D and S7E), or LPS (TLR4, Figures 7D and 7E) to
determine pathway specificity of TRIM function. The results
from all stimulations were summarized in a heatmap to facili-
tate comparison (Figure 7F). All three stimuli increased IFN-b
and ISG54 expression (Figure 7D, Figures S7B and S7D).
IL6 induction was less pronounced in the case of poly I:C
(3-fold) and absent upon LPS stimulation. Similar to the
results found during SeV infection, mRNA targeting of
TRIM1, TRIM8, TRIM13, TRIM25, and TRIM32 attenuated
poly I:C- and LPS-induced IFN-b and ISG54 mRNA induction
(Figure 7E; Figure S7E). However, TRIM38 mRNA targeting
enhanced IFN-b, ISG54, and IL6 expression (Figure 7E; Fig-
ure S7E), suggesting that it may act as a negative regulator
in the TRIF-dependent pathways. These results are in agree-
ment with the enhanced cytokine expression observed in
LPS-stimulated MDDCs with reduced levels of TRIM38
(Figures 6A and 6B).
Zymosan and TLR2-induced cytokine expression was also
reduced compared to the scrambled shRNA control in the
presence of reduced TRIM1, TRIM25, and TRIM32 levels (Fig-
ure S7C). In general, the attenuation seemed less pronounced,
which may have in part resulted from the later time point of
analysis (6 hr p.t. compared to 3–4 hr p.t. for SeV, pIC, LPS).
Throughout the zymosan experiment, cells expressing shRNA I
against TRIM13 for unknown reasons had increased cytokine
levels, which conflicted with results from shRNA II in the
same experiment and results from the other tested stimuli.
However, a third distinct shRNA targeting TRIM13 also attenu-
ated zymosan-mediated cytokine induction (data not shown),
suggesting that TRIM13 knockdown indeed attenuates IFN
and ISG induction.
TRIM8 and TRIM38 mRNA targeting did not attenuate IFN-b
induction, suggesting that these two TRIMs play no substantial
role in the TLR2-mediated IFN-b induction (Figure S7C). Simi-
larly, TRIM38 mRNA targeting did not consistently change
ISG54 induction. In contrast, TRIM8 mRNA targeting consis-
tently enhanced ISG54 expression, suggesting that under
physiological conditions TRIM8 may be a regulator of type I
IFN signaling, but not IFN induction upon TLR2 stimulation. A
role for TRIM8 in IFN regulation has in fact been previously
described (Toniato et al., 2002). We speculate that we onlyd in polyclonal cell populations by RT-qPCR. Subsequently, these cells were
4-MyD88-TRIF axis). At the indicated times, total RNA was isolated and IFN-b,
as mean ± SD.
. Half of each oval unit represents each of the two different shRNAs. Samples
ked green uponR35% enhancement of cytokine induction.
ed cells stimulated for 24 hr with zymosan. Subsequently, these Vero cells were
.
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because under those conditions ISG54 production may have
been in part through IFN-b secretion and IFN-aR engagement.
With the other, shorter stimuli, ISG54 induction was likely
predominantly induced directly through IRF3, which would not
allow observing any attenuation of the IFN signaling pathway
by ISG54 mRNA levels. However, future experiments will be
required to determine whether this is the case.
To confirm the results found during zymosan stimulation and
address biological relevance, we stimulated TRIM mRNA
targeted THP1 cells with zymosan and their supernatants
analyzed for antiviral cytokine levels in a VSV-GFP infection
challenge on Vero cells (Figure S7F). As expected, mock-stim-
ulated or zymosan-containing medium did not protect Vero
cells from infection (Figure 7G, red bars), whereas IFN treat-
ment or supernatant from zymosan-stimulated control cells
protected against viral replication (blue bars). In line with
a minimal or nonexisting role for TRIM8 and TRIM38 in TLR2-
mediated IFN production, their mRNA targeting only minimally
attenuated antiviral cytokine production (Figure 7G). In contrast,
mRNA targeting of TRIM1, TRIM13, TRIM25, and TRIM32
attenuated antiviral cytokine production, thus allowing consid-
erably higher viral replication. These data thus confirm the
requirement of these four TRIM proteins in TLR2-mediated anti-
viral cytokine synthesis.
Overall, TRIM mRNA targeting most considerably affected
IFN-b and ISG54 expression while having less pronounced and
more variable impact on proinflammatory cytokine IL6 synthesis
(Figure 7F). We thus conclude that TRIM proteins have a more
prominent role in the type I IFN system while having limited or
indirect effects on proinflammatory cytokine synthesis (Figures
7F and 7H). Importantly, we demonstrate that TRIM knockdown
resulted in consistent effects on IFN-b induction throughout
different experiments, although certain TRIMs regulated cyto-
kine expression in a cell-type dependent or stimulus-dependent
manner (Table S2).
The combined data from expression and mRNA targeting
experiments (Figures 2, 5, 6, 7; Table S2) support the notion
that TRIM38 is a positive regulator of the RIG-I pathway, while
being a negative regulator of the TRIF-dependent pathways,
with no or minimal importance in MyD88-dependent signaling
(Figures 7F and 7H). This is substantiated by the fact that three
different publications reported similar conclusions while our
manuscript was under revision (Xue et al., 2012; Zhao et al.,
2012a; Zhao et al., 2012b).
Moreover, our results indicate that TRIM25 may also play
a role downstream of RIG-I (Figure 7H). Because TRIM1,
TRIM13, and TRIM32 are seemingly involved in enhancement
of all tested pathways, we predict them to act in a part of the
pathway downstream of the distinct adaptor proteins MAVS-
TRIF-MyD88, which is shared by all three induction routes (Fig-
ure 7H), between TBK1-IKKε and IRF3. Many regulatory mole-
cules have been reported to act at this part of the signaling
pathway and could thus be potential targets for individual TRIMs.
Exogenous TRIM expressionmapping suggested that TRIM13
may act upstream of TBK1-IKKε, whereas TRIM1 may act at the
level of IRF3 (Figure 2I). TRIM8 seemingly plays only a minimal
role in TLR2 induced signaling, suggesting that it may have a
target shared between the TRIF- and MAVS-controlled path-396 Immunity 38, 384–398, February 21, 2013 ª2013 Elsevier Inc.ways (Figure 7H). Thus, with the resolution to be expected
from medium-throughput analyses, we predict most of the
TRIMs studied (both by expression and mRNA targeting) to
act at a level shared between different induction pathways
(TBK1-IKKε to IRF3) or just upstream between the adaptors
TRIF-MAVS and TBK1-IKKε.
DISCUSSION
We report here the complementary DNA cloning of all known
TRIM-encoding genes and systematic analysis of their respec-
tive proteins in innate immune activation. Although some TRIMs
had previously been implicated in innate immune activation, here
we demonstrate that an unprecedented large number of TRIMs
modulates innate immunity and that their transcriptional and
posttranscriptional regulation is complex. It supports the notion
that many human TRIM proteins rapidly evolved and expanded
as part of the innate immune system.
The majority of the studied TRIM proteins contain a RING
domain, which has been shown to facilitate ubiquitin E3 ligase
activity in several TRIM members (Napolitano et al., 2011). Also
our data from expression experiments using RING mutants
demonstrated that all of the six tested TRIMs required an intact
RING domain for efficient antiviral cytokine production.
However, although all of these tested TRIM required their RING
for function, we speculate that this is not the case for all innate
immune enhancing TRIMs because two TRIM-like proteins that
have no RING domain (TRIM14 and TRIM66), still potently
enhanced immune induction.
TRIMs have been classified in subgroups in part according to
their C-terminal domains. Interestingly, TRIMs from all sub-
groups were found to modulate innate immunity. Partially as a
result of low numbers of TRIMs in certain groups, none of them
contained more modulatory members than others. However,
except for TRIM46, all five other members of sub-group I—char-
acterized by C-terminal COS-FN3 and PRY-SPRY domains
(Short and Cox, 2006)—(TRIM1, TRIM9, TRIM18, TRIM36, and
TRIM67) strongly enhanced at least two promoters in the
reporter assays above average. This correlation is even more
striking for all the TRIMs containing a COS domain (subgroup I,
II, and III). Nine out of ten TRIMs containing the COS domain acti-
vated at least one promoter above average, suggesting that their
COS domain may be important for innate immune function.
TRIM5 mRNA targeting did not negatively affect cytokine
expression in our hands, irrespective of the inducer used. This
contrasts with a recent report demonstrating that TRIM5 posi-
tively regulates NF-kB signaling, AP-1 activation and the expres-
sion of several proinflammatory cytokines (Pertel et al., 2011).
Nevertheless, overexpression of both the alpha and delta iso-
forms of TRIM5 strongly enhanced the innate immune reporters
in our assays, which is in linewith the observations by Pertel et al.
The precise reason for a lack of attenuation in our hands upon
TRIM5 mRNA targeting remains currently unclear. We consis-
tently knocked down TRIM5 mRNA levels by 50%–90%, yet
Pertel et al. reported a much more efficient TRIM5 mRNA abla-
tion of 10- to 50-fold. Although our mRNA targeting levels are
sufficient for observing phenotypes for other TRIMs tested, in
the case of TRIM5 the decrease in functional TRIM5 in our hands
may be insufficient for observing a phenotype. Whether this is
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remains to be determined in the future.
A recent manuscript reported the role of a limited set of TRIMs
in NF-kB regulation, and to a lesser extent in IFN regulation (Uchil
et al., 2012). The limited number of TRIMs that the authors
identify as important for IFN regulation in their screen largely
overlaps with the group we report here and have investigated
in more detail by knockdown in various cell types. However,
our approach using an activating stimulus allowed the identifica-
tion of many additional TRIMs that were not recognized previ-
ously. This underpins the fact that most TRIMs act as enhancers
rather that direct activators of innate immune pathways.
In conclusion, our data demonstrate that many TRIM proteins
are important regulators of the innate immune response. Each of
these regulatory TRIMs is likely to act at different steps during
the induction of IFN and proinflammatory cytokines. Our data
open up the field for many follow-up studies addressing the
importance of TRIMs in different cell types, signaling pathways,
and immune disorders in the future. It is feasible that our findings
have only scratched the surface of the complexity of TRIM regu-
lation. Based on the unique nature of the dedication of such
a large protein family to regulation of innate immunity, future
studies hold great promise to expose novel mechanisms and
even paradigms in protein regulation and interplay during signal
transduction.
EXPERIMENTAL PROCEDURES
Isolation, Transduction, and Stimulation of MDDCs
All human research protocols for this work have been reviewed and approved
by the Institutional Review Board of the Mount Sinai School of Medicine.
Peripheral blood mononuclear cells were isolated from buffy coats of healthy
human donors by Ficoll density gradient centrifugation (Histopaque, Sigma
Aldrich) as previously described (Fernandez-Sesma et al., 2006; Haye et al.,
2009). Plated monocytes were transduced as previously described (Berger
et al., 2011). Equal amounts of each virus were added, just sufficient to trans-
duce >95% of the cells. At 5 days posttransduction, MDDCs were either
induced with a final concentration of 0.4 ng/mL LPS (Alexis Biochemicals;
581-008-L002) for 2 hr or infected with 2 HAU of SeV in a M96 well for 4 hr.
Cell Lines with Stable Attenuation of Gene Expression
HEK293T, A549, and THP-1 cells were seeded in 12-well clusters. Sixteen hrs
later, medium was replaced with complete growth medium containing poly-
brene (Sigma) and 2.5 3 105 TU of lentiviruses expressing specific anti-
TRIM shRNAs (Santa Cruz Biotechnology). Cells were selected for puromycin
resistance and polyclonal pools of stable mRNA targeted cells were main-
tained in growth medium containing puromycin for a maximum of ten
passages. THP-1 cells were differentiated into a macrophage-like phenotype
by PMA treatment (for SeV and zymosan inductions) or left in their monocyte-
like phenotype (for poly I:C and LPS stimulations).
IFN Antiviral Activity Assay by VSV-GFP Infection
HEK293T, which were previously selected for increased protein expression
(293T-HiEx), were transfected in triplicate in M24 clusters with per well: 2 ng
RIG-I(2CARD) plasmid in the presence of either 48 ng or 148 ng TRIM plasmid.
Alternatively, THP-1 cells differentiated to their macrophage-like phenotype
were washed and stimulated with 10 mg/mL zymosan. At 32 hr p.t. superna-
tants were harvested and analyzed in an IFN bio-assay on Vero cells.
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